While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Although it looked to be lights out for InflaRx’s C5a antibody vilobelimab in the rare skin disorder pyoderma gangrenosum (PG) last year, the German drugmaker ended 2025 with a glimmer of hope for the ...
Atlanta Falcons quarterback Kirk Cousins gets into reading coverages and speeding up this offense in this in-depth answer to the possibility that coaches aren't teaching reads as much as they used to.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results